Lack of association between Fas rs180082 polymorphism and risk of cervical cancer: an update by meta-analysis

BMC Medical Genetics

Xiandu Su²  Qiliu Peng¹  Wuning Mo¹  Xu Chen¹ 

[1] Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, 22 Shuangyong Road, Nanning 530021, Guangxi, People’s Republic of China;Department of Clinical Laboratory, Nongken Nada Hospital, Nada 571700 Hainan, People’s Republic of China

关键词: Meta-analysis;    Polymorphism;    Cervical cancer;    Fas;   

Others  :  1127661
DOI  :  10.1186/1471-2350-14-71

 received in 2012-08-18, accepted in 2013-07-07,  发布年份 2013

【 摘 要 】

Background

The Fas rs180082 polymorphism has been reported to be associated with cervical cancer susceptibility, yet the results of these previous results have been inconsistent or controversial. The objective of this study was to explore whether the Fas rs180082 polymorphism confers susceptibility to cervical cancer.

Methods

The relevant studies were identified through a search of PubMed, Excerpta Medica Database (Embase), Elsevier Science Direct and Chinese Biomedical Literature Database (CBM) until July 2012. The association between the Fas rs180082 polymorphism and cervical cancer risk was assessed by odds ratios (ORs) together with their 95% confidence intervals (CIs).

Results

A total of 7 case–control studies were eventually identified. We found no association between Fas rs180082 polymorphism and cervical cancer susceptibility in overall population (G versus A: OR = 1.03, 95% CI = 0.99-1.07, P = 0.197; AG + GG versus AA: OR = 1.04, 95% CI = 0.98-1.09, P = 0.176; GG versus AA + AG: OR = 1.04, 95% CI = 0.84–1.31, P = 0.701). In subgroup analysis, similar results were found in Asian (G versus A: OR = 1.06, 95% CI = 0.97–1.15, P = 0.195; AG + GG versus AA: OR = 1.08, 95% CI = 0.98–1.19, P = 0.176; GG versus AA + AG: OR = 0.97, 95% CI = 0.51–1.84, P = 0.935) and African (G versus A: OR = 1.01, 95% CI = 0.97-1.15, P = 0.195; AG + GG versus AA: OR = 0.99, 95% CI = 0.91–1.07, P = 0.739; GG versus AA + AG: OR = 1.09, 95% CI = 0.94–1.25, P = 0.745).

Conclusion

This meta-analysis has shown that there is a lack of association of the Fas rs180082 polymorphisms with cervical cancer susceptibility. However, larger scale primary studies with the consideration of gene–gene and gene–environment interactions are still required to further evaluate the interaction of Fas rs180082 polymorphism with cervical cancer susceptibility.

【 授权许可】

   
2013 Chen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N, et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
• [2]Hausen HZ: Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000, 92(9):690-698.
• [3]Ueda M, Hung YC, Terai Y, Kanda K, Takehara M, Yamashita H, Yamaguchi H, Akise D, Yasuda M, Nishiyama K, et al.: Glutathione S-transferase GSTM1, GSTT1 and p53 codon 72 polymorphisms in human tumor cells. Hum Cell 2003, 16(4):241-251.
• [4]Tsigris C, Chatzitheofylaktou A, Xiromeritis C, Nikiteas N, Yannopoulos A: Genetic association studies in digestive system malignancies. Anticancer Res 2007, 27(5):3577-3587.
• [5]Dockrell DH: Apoptotic cell death in the pathogenesis of infectious diseases. J Infect 2001, 42:227-234.
• [6]Zhang J, Xu X, Liu Y: Activation-induced cell death in T cells and autoimmunity. Cell Mol Immunol 2004, 1:186-192.
• [7]Nagata S: Apoptosis by death factor. Cell 1997, 88(3):355-365.
• [8]Butler LM, Hewett PJ, Butler WJ, Cowled PA: Down-regulation of Fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement. Br J Cancer 1998, 77(9):1454-1459.
• [9]Lee SH, Shin MS, Park WS, Kim SY, Dong SM, Pi JH, Lee HK, Kim HS, Jang JJ, Kim CS, et al.: Alterations of Fas(APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res 1999, 59(13):3068-3072.
• [10]Shimonishi T, Isse K, Shibata F, Aburatani I, Tsuneyama K, Sabit H, Harada K, Miyazaki K, Nakanuma Y: Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Hepatology 2000, 32(4):761-769.
• [11]Chatterjee K, Engelmark M, Gyllensten U, Dandara C, van der Merwe L, Galal U, Hoffman M, Williamson AL, et al.: Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among Black and Mixed-ancestry South Africans. BMC Res Notes 2009, 2:238. BioMed Central Full Text
• [12]Li H, Guo HY, Sun T, Zhou YF, Lin DX, Zhang WH, Qiao J: Association between Fas/Fas L genes promoter polymorphisms and pathogenic risk of cervical cancer. Zhonghua Zhong Liu Za Zhi 2009, 31(1):38-41.
• [13]Kordi Tamandani DM, Sobti RC, Shekari M: Association of Fas-670 gene polymorphism with risk of cervical cancer in North Indian population. Clin Exp Obstet Gynecol 2008, 35(3):183-186.
• [14]Kang S, Dong SM, Seo SS, Kim JW, Park SY: FAS -1377 A/G polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet 2008, 180(1):1-5.
• [15]Zoodsma M, Nolte IM, Schipper M, Oosterom E, van der Steege G, de Vries EG, Te Meerman GJ, van der Zee AG: Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. Int J Gynecol Cancer 2005, 15:282-290.
• [16]Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M, Yamaguchi H, Nishiyama K, Yasuda M, Ueki M: Fas gene promoter -670 polymorphism in gynecological cancer. Int J Gynecol Cancer 2006, 16:179-182.
• [17]Zhang Z, Xue H, Gong W, Wang M, Yuan L, Han S, Zhang Z: FAS promoter polymorphisms and cancer risk:a meta-analysis based on 34 case–control studies. Carcinogenesis 2009, 30(3):487-493.
• [18]Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22(4):719-748.
• [19]DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
• [20]Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558.
• [21]Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560.
• [22]Munafo MR, Clark TG, Flint J: Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Res 2004, 129(1):39-44.
• [23]Nunobiki O, Ueda M, Toji E, Yamamoto M, Akashi K, Sato N, Izuma S, Torii K, Tanaka I, Okamoto Y, et al.: Genetic polymorphism of cancer susceptibility genes and HPV infection in cervical carcinogenesis. Pathol Res Int 1999, 189:12-19.
• [24]Sun T, Zhou Y, Li H, Han X, Shi Y, Wang L, Miao X, Tan W, Zhao D, Zhang X, et al.: FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med 2005, 202(7):967-974.
• [25]Engelmark MT, Renkema KY, Gyllensten UB: No evidence of the involvement of the Fas -670 promoter polymorphism in cervical cancer in situ. Int J Cancer 2004, 112(6):1084-1085.
• [26]Ivansson EL, Gustavsson IM, Magnusson JJ, Steiner LL, Magnusson PK, Erlich HA, Gyllensten UB: Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int J Cancer 2007, 121(11):2451-2457.
• [27]Lai HC, Lin WY, Lin YW, Chang CC, Yu MH, Chen CC, Chu TY: Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction. Gynecol Oncol 2005, 99(1):113-118.
• [28]Lai HC, Sytwu HK, Sun CA, Yu MH, Yu CP, Liu HS, Chang CC, Chu TY: Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 2003, 103(2):221-225.
• [29]Guzman VB, Yambartsev A, Goncalves-Primo A, Silva ID, Carvalho CR, Ribalta JC, Goulart LR, Shulzhenko N, Gerbase-Delima M, Morgun A, et al.: New approach reveals CD28 and IFNG gene interaction in the susceptibility to cervical cancer. Hum Mol Genet 2008, 17(12):1838-1844.
• [30]Ueda M, Hung YC, Terai Y, Yamaguchi H, Saito J, Nunobiki O, Noda S, Ueki M: Fas gene promoter -670 polymorphism (A/G) is associated with cervical carcinogenesis. Gynecol Oncol 2005, 98(1):129-133.
• [31]Zucchi F, da Silva ID, Ribalta JC, de Souza NC, Speck NM, Girão MJ, Brenna SM, Syrjänen KJ: Fas/CD95 promoter polymorphism gene and its relationship with cervical carcinoma. Eur J Gynaecol Oncol 2009, 30(2):142-144.
• [32]Dybikowska A, Sliwinski W, Emerich J, Podhajska AJ: Evaluation of Fas gene promoter polymorphism in cervical cancer patients. Int J Mol Med 2004, 14(3):475-478.
• [33]Lerma E, Romero M, Gallardo A, Pons C, Muñoz J, Fuentes J, Lloveras B, Catasus L, Prat J: Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma. Virchows Arch 2008, 452(1):65-74.
• [34]Zörnig M, Hueber A, Baum W, Evan G: Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 2001, 1551(2):F1-F37.
• [35]Kanemitsu S, Ihara K, Saifddin A, Otsuka T, Takeuchi T, Nagayama J, Kuwano M, Hara T: A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 2002, 29(6):1183-1188.
• [36]Zhu Q, Wang T, Ren J, Hu K, Liu W, Wu G: FAS -670A/G polymorphism: a biomarker for the metastasis of nasopharyngeal carcinoma in a Chinese population. Clin Chim Acta 2010, 411(3–4):179-183.
• [37]Park JY, Lee WK, Jung DK, Choi JE, Park TI, Lee EB, Cho S, Park JY, Cha SI, Kim CH, et al.: Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer. Clin Cancer Res 2009, 15(5):1794-1800.
• [38]Wang LE, Cheng L, Spitz MR, Wei Q: Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer 2003, 42(1):1-8.
• [39]Zhou RM, Wang N, Chen ZF, Duan YN, Sun DL, Li Y: Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma. J Gastroenterol Hepatol 2010, 25(3):555-561.
• [40]Farre L, Bittencourt AL, Silva-Santos G, Almeida A, Silva AC, Decanine D, Soares GM, Alcantara LC Jr, Van Dooren S, Galvão-Castro B, et al.: Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. J Leukoc Biol 2008, 83(1):220-222.
• [41]Hu Y, Xu Y, Wang Y, Ouyang T, Li JF, Wang TF, Fan ZQ, Fan T, Lin BY, Geng PL, et al.: Prognostic role of apoptosis-related gene Fas-1377 and -670 polymorphisms in breast cancer. Zhonghua Zhong Liu Za Zhi 2009, 31(2):104-107.